BioAge, BKV shares end their first trading day flat after earlier gains
Obesity-drug developer BioAge Labs Inc. gained about 20% after its initial public offering on Thursday, while natural-gas ...
Natgas Producer BKV Valued at $1.56 Billion in NYSE Debut
(Reuters) - Shares of BKV rose 3.1% in their debut on the New York Stock Exchange on Thursday, giving the U.S. natural gas ...
Seeking Alpha4d
IPO Roundup: Guardian Pharmacy Services, BKV Corp and more
Obesity drug developer BioAge Labs (BIOA ... Additionally, natural gas and related fuels producer BKV (BKV) is looking to raise about $300M in a U.S. IPO, which the company aims to use to repay ...
Stock Market Today: Dow up 200 points, S&P 500 hits record high after upbeat economic data
Texas-based Barnett Shale driller BKV Inc. priced below the estimated range, while obesity-drug developer BioAge Labs Inc. priced midrange ahead of their first day of trading on Thursday. As the ...
BioAge, obesity drug developer, upsizes proposed IPO
BioAge Labs (BIOA), which is developing a drug to augment popular weight-loss medications such as Wegovy and Zepbound, has upsized its proposed IPO. Read more here.
Initial public offerings scheduled to debut next week
NEW YORK (AP) — The following is a list of initial public offerings planned for the coming week. Sources include IPO ETF manager Renaissance Capital, and SEC filings.
Capital Markets
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...
SFGate8d
Initial public offerings scheduled to debut next week
Proposed NYSE symbol BKV. Business: US natural gas producer operating in the Barnett and Marcellus Shale. BioAge Labs - Richmond, Calif., 7.5 million shares, priced at $17-$19, managed by Goldman ...